Literature DB >> 18299795

Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins.

Lidice Bernardo1, Lisset Hermida, Jorge Martin, Mayling Alvarez, Irina Prado, Carlos López, Rafael Martínez, Rosmari Rodríguez-Roche, Aida Zulueta, Laura Lazo, Delfina Rosario, Gerardo Guillén, María G Guzmán.   

Abstract

The suitability of dengue 2 envelope domain III recombinant fusion proteins [(fusion (PD5) and insertion (PD3) variants)] for inducing functional antibodies and a protective immune response in nonhuman primates has been reported. However, the evaluation of the antibody response after immunization did not correlate with the protection data as measured by viremia detection. Here, we characterized the anamnestic immune response after viral challenge in monkeys immunized with the dengue 2 recombinant proteins in an attempt to define correlates of protection useful for vaccine studies. Monkeys immunized with PD5 (most protected group) exhibited an earlier increase in the anti-DENV-2 IgM response after challenge compared to control animals. Hemagglutination-inhibiting (HAI) antibodies were increased significantly earlier in PD5-immunized animals compared to those immunized with PD3. The fully protected monkeys showed the earliest HAI antibody response. These results underline the usefulness of the anamnestic antibody response for supporting protection data. The induction of an early HAI and IgM antibody response after challenge suggest a protective role against dengue virus (DENV) infection in monkeys, supporting their use as correlates of protection in vaccine studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18299795     DOI: 10.1007/s00705-008-0050-9

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  16 in total

1.  Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice.

Authors:  Juergen Zlatkovic; Karin Stiasny; Franz X Heinz
Journal:  J Virol       Date:  2010-12-08       Impact factor: 5.103

2.  Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates.

Authors:  Sean P McBurney; Justine E Sunshine; Sarah Gabriel; Jeremy P Huynh; William F Sutton; Deborah H Fuller; Nancy L Haigwood; William B Messer
Journal:  Vaccine       Date:  2016-04-13       Impact factor: 3.641

3.  Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.

Authors:  Julia C Frei; Ariel S Wirchnianski; Jennifer Govero; Olivia Vergnolle; Kimberly A Dowd; Theodore C Pierson; Margaret Kielian; Mark E Girvin; Michael S Diamond; Jonathan R Lai
Journal:  J Virol       Date:  2018-08-29       Impact factor: 5.103

4.  An in-depth analysis of original antigenic sin in dengue virus infection.

Authors:  Claire M Midgley; Martha Bajwa-Joseph; Sirijitt Vasanawathana; Wannee Limpitikul; Bridget Wills; Aleksandra Flanagan; Emily Waiyaiya; Hai Bac Tran; Alison E Cowper; Pojchong Chotiyarnwong; Pojchong Chotiyarnwon; Jonathan M Grimes; Sutee Yoksan; Prida Malasit; Cameron P Simmons; Juthathip Mongkolsapaya; Gavin R Screaton
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

5.  Natural strain variation and antibody neutralization of dengue serotype 3 viruses.

Authors:  Wahala M P B Wahala; Eric F Donaldson; Ruklanthi de Alwis; Mary Ann Accavitti-Loper; Ralph S Baric; Aravinda M de Silva
Journal:  PLoS Pathog       Date:  2010-03-19       Impact factor: 6.823

6.  Comprehensive mapping of functional epitopes on dengue virus glycoprotein E DIII for binding to broadly neutralizing antibodies 4E11 and 4E5A by phage display.

Authors:  Julia C Frei; Margaret Kielian; Jonathan R Lai
Journal:  Virology       Date:  2015-09-02       Impact factor: 3.616

7.  Primary and secondary infections of Macaca fascicularis monkeys with Asian and American genotypes of dengue virus 2.

Authors:  Lidice Bernardo; Alienys Izquierdo; Irina Prado; Delfina Rosario; Mayling Alvarez; Emidalys Santana; Jorge Castro; Rafael Martínez; Rosmari Rodríguez; Luis Morier; Gerardo Guillén; María G Guzmán
Journal:  Clin Vaccine Immunol       Date:  2007-12-19

8.  A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates.

Authors:  Xiao-Feng Li; Yong-Qiang Deng; Hui-Qiang Yang; Hui Zhao; Tao Jiang; Xue-Dong Yu; Shi-Hua Li; Qing Ye; Shun-Ya Zhu; Hong-Jiang Wang; Yu Zhang; Jie Ma; Yong-Xin Yu; Zhong-Yu Liu; Yu-Hua Li; E-De Qin; Pei-Yong Shi; Cheng-Feng Qin
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

9.  Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity.

Authors:  Claire M Midgley; Aleksandra Flanagan; Hai Bac Tran; Wanwisa Dejnirattisai; Kriangkrai Chawansuntati; Amonrat Jumnainsong; Wiyada Wongwiwat; Thaneeya Duangchinda; Juthathip Mongkolsapaya; Jonathan M Grimes; Gavin R Screaton
Journal:  J Immunol       Date:  2012-04-09       Impact factor: 5.422

10.  Testing of novel dengue virus 2 vaccines in African green monkeys: safety, immunogenicity, and efficacy.

Authors:  Katherine M Smith; Kavita Nanda; Carla J Spears; Amanda Piper; Mariana Ribeiro; Michelle Quiles; Caitlin M Briggs; Gwynneth S Thomas; Malcolm E Thomas; Dennis T Brown; Raquel Hernandez; Victoria McCarl
Journal:  Am J Trop Med Hyg       Date:  2012-08-13       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.